✦ LIBER ✦

The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia

✍ Scribed by William G. Woods; Frederick B. Ruymann; Beatrice C. Lampkin; Jonathan D. Buckley; Irwin D. Bernstein; Ashok K. Srivastava; W. Anthony Smithson; Denis R. Benjamin; Stephen A. Feig; Tae H. Kim; Lorrie F. Odom; Robert J. Wells; G. Denman Hammond

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 809 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900915)66:6<1106::aid-cncr2820660605>3.0.co;2-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute nonlymphocytic leukem

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

The role of cytosine arabinoside mainten

The role of cytosine arabinoside maintenance in acute nonlymphoblastic leukemia

✍ P. N. Grozea; Dr. R. H. Bottomley; M. T. Shaw; H. Tu; R. E. Chanes; P. T. Condit 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB 👁 2 views

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Epirubicin and cytosine arabinoside for

Epirubicin and cytosine arabinoside for the induction therapy of childhood acute nonlymphocytic leukemia

✍ Dr. Der-Cherng Liang; Chang-Jen Jiang 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB 👁 2 views

High-dose cytosine arabinoside in the tr

High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens

✍ Herzig, Roger H. ;Herzig, Geoffrey P. ;Lazarus, Hillard M. ;Wolff, Steven N. ;Ph 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

High-dose cytosine arabinoside (Ara-C) was used in adult patients with refractory acute nonlymphoblastic leukemia, either alone (3 g/m2 every 12 h X 12 doses) or with 3 additional days of anthracycline antibiotics. The systemic toxicities were similar for both groups without an increase in the group

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete